source
- FDA approves Roivant's brepocitinib for rare autoimmune disease dermatomyositisOn Thursday the U.S. Food and Drug Administration gave its nod to a new therapy from Roivant Sciences and its subsidiary Priovant. The oral medication, brepocitinib, will be sold under the brand na…
- Hospitals Prepare Lobbying Effort to Counter $1 Trillion Health Care Funding CutsHospitals are gearing up to lobby Congress after a projected $1 trillion reduction in health‑care spending, which was part of recent tax‑cut legislation. Hospital leaders say they will seek higher…